Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
ICF Q4 2025 Earnings Call - Non-federal growth led by commercial energy to drive 2026 recovery
ICF closed 2025 with a clear inflection in its business mix, offsetting a 7.3% revenue decline with stronger margins and a big shift toward non-federal clients. Management guided to a return to revenu...
- Company delivered Q4 revenue of $443.7 million and full-year 2025 revenue of $1.87 billion, down 7.3% year over year but within guidance ranges.
- Management expects 2026 revenues of $1.89 billion to $1.96 billion, a roughly 3% midpoint increase, and non-GAAP EPS of $6.95 to $7.25, roughly 5% midpoint growth.
- Non-federal clients drove the rebound, with non-federal revenues up 14% in 2025 and expected to exceed 60% of total revenues in 2026.
- +11 more takeaways
Applied Optoelectronics Inc. Q4 2025 Earnings Call - 800G Ramp to Drive 2026 Growth, Capacity Not Demand
Applied Optoelectronics closed 2025 with record revenue of $456 million, driven by a big CATV recovery and a rapidly growing data center business. Management emphasized that the next phase is an 800G ...
- Record full-year 2025 revenue of $456 million, up 83% versus 2024; Q4 revenue was $134.3 million, in-line with guidance.
- Data center revenue for 2025 was $196 million, up 32% year-over-year; Q4 data center revenue was $74.9 million, up 69% year-over-year and 70% sequentially.
- CATV revenue nearly tripled to $245 million in 2025; Q4 CATV revenue was $54 million, down 24% sequentially from a record Q3 but in line with guidance.
- +12 more takeaways
Rocket Companies Q4 2025 Earnings Call - AI-driven integrations and Compass alliance turbocharge recapture and market-share gains
Rocket closed 2025 with a statement of scale, not a whisper. The company beat Q4 revenue guidance, delivered its highest fourth-quarter net rate lock volume and gain on sale margin since 2021, and pos...
- Q4 adjusted revenue was $2.44 billion, beating the top end of guidance by $140 million.
- CFO reported $42 billion in net rate lock volume for Q4, $36 billion excluding the correspondent channel, with a gain on sale margin of 320 basis points.
- Adjusted EBITDA rose to $592 million in Q4 from $349 million in Q3, expanding margin to 24% versus 20% in Q3.
- +15 more takeaways
Caris Life Sciences Q4 2025 Earnings Call - Achieve 1 interim validates Caris Detect launch and funds commercial and R&D expansion
Caris closed 2025 with a blowout quarter and a rare combination in this sector: rapid top-line growth and positive GAAP profitability. Q4 revenue jumped 125% year over year to $293 million, driven by ...
- Q4 2025 total revenue rose 125% year over year to $293.0 million, driven primarily by molecular profiling services at $282.0 million.
- Full year 2025 molecular profiling revenue grew 120% to $766.7 million, with total cases near 199,300 for the year and volume growth of about 22% year over year.
- Caris reported positive GAAP net income of $82 million in Q4 and adjusted EBITDA of $106 million for the quarter, with full year adjusted EBITDA of $138 million and free cash flow of $67 million for 2025.
- +12 more takeaways
Zscaler Q2 Fiscal 2026 Earnings Call - AI agents and Zero Trust drive upgraded guidance
Zscaler delivered a beat-and-raise quarter, driven by strong demand for its Zero Trust Exchange and a newly amplified AI security narrative. ARR ended the quarter at $3.4 billion, revenue was $816 mil...
- Total ARR reached $3.4 billion, up 25% year-over-year, with net new ARR of $156 million in Q2, up 19% year-over-year.
- Revenue beat at $816 million, growing 26% year-over-year and 4% sequentially.
- Management raised full-year ARR guidance to $3.730 billion-$3.745 billion, implying ~24% ARR growth, and raised revenue guidance for fiscal 2026 to $3.309 billion-$3.322 billion.
- +12 more takeaways
Figure Technology Solutions Q4 2025 Earnings Call - Figure Connect exceeds 50% of volume, accelerating a capital-light marketplace shift
Figure used Q4 to prove the operational thesis: Figure Connect is moving from pilot to core. For the first time, more than half of consumer loan marketplace volume flowed through Connect, pushing the ...
- Figure Connect hit a milestone, accounting for more than 50% of consumer loan marketplace volume in Q4, a fast ramp from its June 2024 launch and a structural step toward a capital-light model.
- Consumer loan marketplace volume was $2.7 billion in Q4, up 131% year-over-year, with 307 partners now on the platform.
- Adjusted net revenue was $158 million, up 106% year-over-year; adjusted EBITDA was $81.3 million, up ~426% year-over-year, with adjusted EBITDA margin expanding to 51.6%.
- +11 more takeaways
PAR Technology Q4 2025 Earnings Call - AI-first platform momentum drives multi-product wins and ARR to $315.4M
PAR closed a strong Q4 and a turnaround year, with revenue of $120.1 million in the quarter and full-year revenue of $455.5 million. The company reported its third consecutive quarter of non-GAAP prof...
- Q4 revenue was $120.1 million, up 14% year-over-year; full-year revenue was $455.5 million, up $105 million versus prior year.
- PAR exited Q4 with ARR of $315.4 million, representing ~15% organic ARR growth year-over-year, and reported $17 million incremental ARR in Q4 (record).
- Subscription services represented 63% of Q4 revenue at $76 million, up 18% year-over-year, and subscription services grew 40% for the full year per management.
- +12 more takeaways
Ginkgo Bioworks Q4 2025 Earnings Call - Ginkgo doubles down on autonomous labs, spins off biosecurity
Ginkgo used the quarter to draw a hard line in the sand. Management will pivot the company into the autonomous lab category as its core strategy for 2026, reallocating capital and operational focus to...
- CEO Jason Kelly announced an explicit strategic pivot: 2026 will focus on winning the autonomous lab category, reallocating capital and attention away from other initiatives.
- Ginkgo will divest its biosecurity business into a private entity, keeping a minority stake, to free up capital and bring defense-focused investors into that business.
- Management plans to systematically decommission traditional benches and work cells, migrating internal R&D onto a single large autonomous lab in Boston called Nebula as a commercial proof point.
- +12 more takeaways
Natera Q4 2025 Earnings Call - MRD volume surge and margin breakout set stage for $2.62–2.7B 2026 guide
Natera closed 2025 with a blowout quarter, driven by MRD adoption and operational gains. The company processed about 924,000 tests in Q4, including a record 225,000 MRD clinical units, producing $666 ...
- Q4 volume and revenue outperformed: ~924,000 tests processed, $666M revenue, about $6M ahead of the January pre-announce, roughly 40% revenue growth year-over-year.
- MRD momentum is the engine: 225,000 MRD clinical units in Q4, up about 56% versus Q4 2024; management estimates over 50% of US oncologists ordered a Signatera test in the quarter.
- Gross margin expansion was material: reported margin 66.9% in Q4, with organic gross margin 63.7% after stripping ~$60M of revenue true-ups; management sees additional margin upside in 2026.
- +16 more takeaways
Organogenesis Holdings, Inc. Q4 2025 Earnings Call - Record Q4 revenue, but CMS December commentary sparks near-term utilization shock and 2026 revenue guidance cut
Organogenesis closed 2025 with a blowout quarter, reporting $225.1 million of net product revenue in Q4, driven by an 83% year-over-year surge in advanced wound care and materially better margins. Man...
- Q4 2025 net product revenue $225.1 million, up 78% year-over-year and 50% sequentially, beating prior guidance by a wide margin.
- Advanced wound care sales jumped 83% year-over-year in Q4 and were the primary driver of the record quarter.
- Surgical and Sports Medicine sales were down 2% in Q4 but up 12% for full-year 2025, led by PuraPly growth.
- +13 more takeaways